Product How it works Pricing Blog FAQ About Contact
UroGen Pharma

UroGen Pharma (NASDAQ: URGN) revenue

UroGen Pharma reported revenue of $109.8m for fiscal 2025, 21.4% more than in fiscal 2024 ($90.4m). Since fiscal 2016 its revenue has grown by 526.3%, an average growth of 22.6% a year.

UroGen Pharma has grown its revenue for 6 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2019, −98.4%.

Revenue, in millions of US dollars17.520168.220171.120180.0201911.8202048.0202164.4202282.7202390.42024109.82025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$109.8m+21.4%−$124.9m−113.7%
2024$90.4m+9.3%−$96.8m−107.1%
2023$82.7m+28.5%−$65.5m−79.2%
2022$64.4m+34.0%−$79.0m−122.8%
2021$48.0m+307.2%−$92.3m−192.1%
2020$11.8m+65,450.0%−$126.7m−1,074.2%
2019$0.0m−98.4%−$109.5m−608,211.1%
2018$1.1m−86.2%−$77.2m−6,842.2%
2017$8.2m−53.5%−$20.0m−244.5%
2016$17.5m—$0.8m4.6%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

UroGen Pharma revenue compared with its sector

By revenue for its latest fiscal year, UroGen Pharma ranks 280th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; UroGen Pharma, 21.4%.

RankCompanyRevenueRevenue growth
278thImmunitybio$113.3m668.3%
279thAnika Therapeutics$112.8m−5.9%
280thUroGen Pharma$109.8m21.4%
281stCentury Therapeutics$109.2m1,556.8%
282ndZevra Therapeutics$106.5m350.9%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of UroGen Pharma

How much revenue did UroGen Pharma make in fiscal 2025?
UroGen Pharma reported revenue of $109.8m for fiscal 2025, compared with $90.4m in fiscal 2024.
How much has the revenue of UroGen Pharma grown?
Between fiscal 2016 and fiscal 2025 it went from $17.5m to $109.8m: 526.3% more, an average growth of 22.6% a year.
What was the best year for revenue at UroGen Pharma?
Of its last 10 fiscal years, fiscal 2025, with $109.8m.
Where does UroGen Pharma rank in its sector by revenue?
It ranks 280th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for UroGen Pharma come from?
From the annual report (Form 10-K) that UroGen Pharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that UroGen Pharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on UroGen Pharma: the UroGen Pharma page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.